Genetic variant | Patients | Controls | |||||
---|---|---|---|---|---|---|---|
No. | (%) | No. | (%) | P a | ORa | 95% CIa | |
HLA DR3-DQ2-C4AQ0 | 61 | (43) | 42 | (21) | <0.0001 | 2.8 | 1.7–4.5 |
FcγRIIa R/R | 46 | (32) | 51 | (26) | 0.18 | 1.4 | 0.86–2.2 |
FcγRIIIa F/F | 68 | (48) | 90 | (45) | 0.66 | 1.1 | 0.72–1.7 |
MBL-low | 19 | (13) | 28 | (14) | 0.88 | 0.94 | 0.50–1.8 |
IL-1 Ra 2/2 | 14 | (9.8) | 14 | (7.0) | 0.42 | 1.4 | 0.66–3.1 |
HLA DR3-DQ2-C4AQ0 / FcγRIIa R/R | 20 | (14) | 7 | (3.5) | 0.0005 | 4.5 | 1.8–10.9 |
HLA DR3-DQ2-C4AQ0 / FcγRIIIa F/F | 29 | (20) | 19 | (9.5) | 0.007 | 2.4 | 1.3–4.5 |
HLA DR3-DQ2-C4AQ0 / MBL-low | 11 | (7.7) | 5 | (2.5) | 0.04 | 3.3 | 1.1–9.6 |
HLA DR3-DQ2-C4AQ0 / IL-1 Ra 2/2 | 4 | (2.8) | 3 | (1.5) | 0.46 | 1.9 | 0.42–8.6 |
FcγRIIa R/R / FcγRIIIa F/F | 31 | (22) | 32 | (16) | 0.20 | 1.5 | 0.84–2.5 |
FcγRIIa R/R / MBL-low | 3 | (2.1) | 6 | (3.0) | 0.74 | 0.69 | 0.17–2.8 |
FcγRIIa R/R / IL-1 Ra 2/2 | 8 | (5.6) | 1 | (0.5) | 0.005 | 11.8 | 1.5–95.4 |
FcγRIIIa F/F / MBL-low | 8 | (5.6) | 12 | (6.0) | 1.0 | 0.92 | 0.37–2.3 |
FcγRIIIa F/F / IL-1 Ra 2/2 | 8 | (5.6) | 4 | (2.0) | 0.13 | 2.9 | 0.86–9.8 |
MBL-low / IL-1 Ra 2/2 | 1 | (0.7) | 0 | (0.0) | 0.42 | 4.2 | 0.17–104 |